NO980279L - Fremgangsmåte til detektering av lungesykdom - Google Patents
Fremgangsmåte til detektering av lungesykdomInfo
- Publication number
- NO980279L NO980279L NO980279A NO980279A NO980279L NO 980279 L NO980279 L NO 980279L NO 980279 A NO980279 A NO 980279A NO 980279 A NO980279 A NO 980279A NO 980279 L NO980279 L NO 980279L
- Authority
- NO
- Norway
- Prior art keywords
- lung
- acceptable salt
- sample
- mucus
- composition
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/007—Pulmonary tract; Aromatherapy
- A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
- A61K9/0078—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a nebulizer such as a jet nebulizer, ultrasonic nebulizer, e.g. in the form of aqueous drug solutions or dispersions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/14—Alkali metal chlorides; Alkaline earth metal chlorides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/10—Expectorants
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pulmonology (AREA)
- Dispersion Chemistry (AREA)
- Inorganic Chemistry (AREA)
- Otolaryngology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Molecular Biology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Measuring Pulse, Heart Rate, Blood Pressure Or Blood Flow (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Investigating Or Analysing Biological Materials (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Saccharide Compounds (AREA)
Abstract
Det er beskrevet en fremgangsmåte til å lette oppnåelsen av en slimprøve fra minst en lunge hos et subjekt som omfatter administrering til minst en lunge hos subjektet, i en mengde effektiv til å hydrere lungeslimsekreter og/eller stimulere cilia slagfrekvens deri, uridin 5'-trifosfat, en aktiv analog derav, eller et farmasøytisk akseptabelt salt av begge derav, og eventuelt samtidig administrering til nevnte minst ene lunge av et fysiologisk akseptabelt salt i en mengde som er effektiv til å hydrere lungeslimsekreter deri. En spytt- eller slimprøve blir deretter oppsamlet fra nevnte minst ene lunge, hvor prøven deretter kan analyseres for lungesykdom. Farmasøytiske sammensetninger som er nyttig til å utføre fremgangsmåten omfatter UTP eller et salt derav, alene eller i kombinasjon med et fysiologisk akseptabelt salt, eller et farmasøytisk akseptabelt salt av begge derav. Sammensetningen kan være en flytende/væskesuspensjon sammensetning eller en tørr pulversammensetning.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US08/509,052 US5628984A (en) | 1995-07-31 | 1995-07-31 | Method of detecting lung disease |
PCT/US1996/012377 WO1997005195A1 (en) | 1995-07-31 | 1996-07-24 | Method of detecting lung disease |
Publications (2)
Publication Number | Publication Date |
---|---|
NO980279L true NO980279L (no) | 1998-01-21 |
NO980279D0 NO980279D0 (no) | 1998-01-21 |
Family
ID=24025091
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
NO980279A NO980279D0 (no) | 1995-07-31 | 1998-01-21 | Fremgangsmåte til detektering av lungesykdom |
Country Status (17)
Country | Link |
---|---|
US (4) | US5628984A (no) |
EP (1) | EP0841900B1 (no) |
JP (2) | JP3623237B2 (no) |
KR (1) | KR100283306B1 (no) |
CN (1) | CN1121441C (no) |
AT (1) | ATE276740T1 (no) |
AU (1) | AU705528B2 (no) |
BR (1) | BR9610059A (no) |
CA (1) | CA2226892A1 (no) |
DE (1) | DE69633449T2 (no) |
ES (1) | ES2229281T3 (no) |
IL (1) | IL122803A0 (no) |
MX (1) | MX9800933A (no) |
NO (1) | NO980279D0 (no) |
NZ (1) | NZ313864A (no) |
WO (1) | WO1997005195A1 (no) |
ZA (1) | ZA966425B (no) |
Families Citing this family (99)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5948768A (en) * | 1995-04-13 | 1999-09-07 | Milkhaus Laboratory | Treatment of otitis media by sublingual administration of DNA |
WO1996032138A1 (en) * | 1995-04-13 | 1996-10-17 | Milkhaus Laboratory, Inc. | Methods for treating respiratory disease |
US6096721A (en) * | 1995-04-13 | 2000-08-01 | Milkhaus Laboratory, Inc. | Method for treating mucositis by sublingual administration of DNA |
US5635160A (en) | 1995-06-07 | 1997-06-03 | The University Of North Carolina At Chapel Hill | Dinucleotides useful for the treatment of cystic fibrosis and for hydrating mucus secretions |
US5628984A (en) * | 1995-07-31 | 1997-05-13 | University Of North Carolina At Chapel Hill | Method of detecting lung disease |
US6319908B1 (en) | 1996-07-03 | 2001-11-20 | Inspire Pharmaceuticals, Inc. | Method for large-scale production of di(uridine 5′-tetraphosphate) and salts thereof |
US5968913A (en) * | 1996-07-03 | 1999-10-19 | Inspire Pharmaceuticals, Inc. | Pharmaceutical compositions of uridine triphosphate |
US5763447C1 (en) | 1996-07-23 | 2002-05-07 | Inspire Pharmaceuticals | Method of preventing or treating pneumonia in immobilized patients with uridine triphosphates and related compounds |
US6159952A (en) * | 1996-11-07 | 2000-12-12 | Inspire Pharmaceuticals, Inc. | Method of treating bronchitis with uridine triphosphate and related compounds |
US6998121B2 (en) | 2003-01-23 | 2006-02-14 | Milkhaus Laboratory, Inc. | Method of treatment of connective tissue disorders by administration of streptolysin O |
DK1012154T3 (da) | 1997-07-25 | 2004-07-26 | Inspire Pharmaceuticals Inc | Salte af di(uridin-5'-tetraphosphat), fremgangsmåde til fremstilling og anvendelser deraf |
US6872710B2 (en) * | 1997-07-25 | 2005-03-29 | Inspire Pharmaceuticals, Inc. | Di(uridine 5′)-tetraphosphate and salts thereof |
TW593331B (en) | 1997-07-25 | 2004-06-21 | Inspire Pharmaceuticals Inc | Method for large-scale production of di(uridine 5')-tetraphosphate and salts thereof |
CA2300146A1 (en) * | 1997-08-29 | 1999-03-04 | Richard C. Boucher, Jr. | Use of uridine 5'-diphosphate and analogs thereof for the treatment of lung diseases |
US6926911B1 (en) * | 1998-12-22 | 2005-08-09 | The University Of North Carolina At Chapel Hill | Compounds and methods for the treatment of airway diseases and for the delivery of airway drugs |
CA2356637C (en) * | 1998-12-22 | 2011-09-13 | The University Of North Carolina At Chapel Hill | Compounds and methods for the treatment of airway diseases and for the delivery of airway drugs |
AR023088A1 (es) | 1999-02-26 | 2002-09-04 | Inspire Pharmaceuticals Inc | Uso de disfosfatos de uridina, adenina y citidina y analogos de los mismos para la manufactura de un medicamento para la estimulacion de la hidratacion delas mucosas. |
EP1190249A2 (en) * | 1999-06-08 | 2002-03-27 | University Of Iowa Research Foundation | Compounds and methods to enhance raav transduction |
US7241447B1 (en) * | 1999-10-07 | 2007-07-10 | University Of Iowa Research Foundation | Adeno-associated virus vectors and uses thereof |
US7452870B2 (en) * | 2000-08-21 | 2008-11-18 | Inspire Pharmaceuticals, Inc. | Drug-eluting stents coated with P2Y12 receptor antagonist compound |
US7018985B1 (en) | 2000-08-21 | 2006-03-28 | Inspire Pharmaceuticals, Inc. | Composition and method for inhibiting platelet aggregation |
US7115585B2 (en) * | 2000-08-21 | 2006-10-03 | Inspire Pharmaceuticals, Inc. | Compositions for treating epithelial and retinal tissue diseases |
JP2005508297A (ja) | 2001-06-25 | 2005-03-31 | インスパイアー ファーマシューティカルズ,インコーポレイティド | P2yプリン受容体作用物質による関節潤滑 |
JP3823162B2 (ja) * | 2001-07-31 | 2006-09-20 | 株式会社エイアンドティー | 臨床検査分析装置、臨床検査分析方法および臨床検査分析プログラム |
TW200300692A (en) * | 2001-11-06 | 2003-06-16 | Inspire Pharmaceuticals Inc | Method for treating or preventing inflammatory diseases |
US20060196365A1 (en) * | 2001-12-11 | 2006-09-07 | Garman Michael H | Combined water cooler and hot beverage maker |
US6858615B2 (en) | 2002-02-19 | 2005-02-22 | Parion Sciences, Inc. | Phenyl guanidine sodium channel blockers |
US7435724B2 (en) * | 2002-02-27 | 2008-10-14 | Inspire Pharmaceutical, Inc. | Degradation-resistant mononucleoside phosphate compounds |
US20050220720A1 (en) * | 2002-05-02 | 2005-10-06 | David Edwards | Formulations limiting spread of pulmonary infections |
CA2483917C (en) | 2002-05-02 | 2013-07-30 | President And Fellows Of Harvard College | Formulations limiting spread of pulmonary infections |
US7629312B2 (en) | 2003-01-23 | 2009-12-08 | Milkhaus Laboratory, Inc. | Method of treatment of tendonitis by administration of streptolysin O |
CA2520016A1 (en) * | 2003-03-31 | 2004-10-21 | University Of Iowa Research Foundation | Pharmico-gene therapy of epithelial sodium channel associated disorders |
EP2617709B8 (en) | 2003-06-26 | 2022-12-21 | Biotron Limited | Guanidine derivatives as antiviral agents |
US20090253714A1 (en) * | 2003-08-20 | 2009-10-08 | Johnson Michael R | Methods of reducing risk of infection from pathogens |
US7745442B2 (en) | 2003-08-20 | 2010-06-29 | Parion Sciences, Inc. | Methods of reducing risk of infection from pathogens |
JP2007513888A (ja) * | 2003-11-24 | 2007-05-31 | ユニバーシティ オブ ノース カロライナ アット チャペル ヒル | 縮合環ジカチオン性抗原虫剤及びそれらのプロドラッグ |
US20050207983A1 (en) | 2004-03-05 | 2005-09-22 | Pulmatrix, Inc. | Formulations decreasing particle exhalation |
WO2005086754A2 (en) * | 2004-03-08 | 2005-09-22 | Georgia State University Research Foundation, Inc. | Dicationic compounds for activity against trichomonas vaginalis |
US20070099968A1 (en) * | 2004-06-26 | 2007-05-03 | Biotron Limited | Antiviral compounds and methods |
GB0417886D0 (en) * | 2004-08-11 | 2004-09-15 | Univ Cardiff | Method and means for enhanced pulmonary delivery |
EP1874801A4 (en) | 2005-03-07 | 2009-03-25 | Univ North Carolina | RECA ACTIVITY INHIBITORS TO CONTROL ANTIBIOTIC-RESISTANT BACTERIAL PATHOGENS |
AU2006201739A1 (en) * | 2005-05-05 | 2006-11-23 | The University Of North Carolina At Chapel Hill | Synthesis and antiprotozoal activity of dicationic 3,5-diphenylisoxazoles |
NZ593475A (en) * | 2005-05-18 | 2012-12-21 | Pulmatrix Inc | Calcium salts for reducing exhalation of infectious bioaerosol particles |
US7964619B2 (en) | 2005-06-03 | 2011-06-21 | The University Of North Carolina At Chapel Hill | Teraryl components as antiparasitic agents |
AU2006202083A1 (en) | 2005-06-03 | 2006-12-21 | Reto Brun | Linear dicationic terphenyls and their aza analogues as antiparasitic agents |
US20100249175A1 (en) * | 2005-12-02 | 2010-09-30 | Wilson W David | Dicationic compounds which selectively recognize G-quadruplex DNA |
AU2007243184A1 (en) * | 2006-04-28 | 2007-11-08 | University Of Iowa Research Foundation | Methods and compounds to modulate parvovirus transduction of mammalian cells or to alter virus infection, method to identify a viral receptor or co-receptor |
US20080260863A1 (en) * | 2007-04-20 | 2008-10-23 | Pre Holding, Inc. | Compositions for mucociliary clearance and methods for administering same |
JP2010531304A (ja) | 2007-06-18 | 2010-09-24 | ユニバーシティ オブ ルイビル リサーチ ファウンデーション、インコーポレイテッド | 抗悪性腫瘍活性を有するpfkfb3阻害物質ファミリー |
WO2009045536A2 (en) * | 2007-10-05 | 2009-04-09 | The University Of North Carolina At Chapel Hill | Receptor targeted oligonucleotides |
CA2702094C (en) | 2007-10-10 | 2018-05-01 | Parion Sciences, Inc. | Delivering osmolytes by nasal cannula |
WO2009051796A2 (en) * | 2007-10-17 | 2009-04-23 | The University Of North Carolina At Chapel Hill | 2,5-diaryl selenophene compounds, aza 2,5-diaryl thiophene compounds, and their prodrugs as antiprotozoal agents |
KR20100135886A (ko) | 2008-04-09 | 2010-12-27 | 더 유니버시티 오브 노쓰 캐롤라이나 엣 채플 힐 | 액틴 세포 골격의 재배열 및 세포간 갭 형성을 조절하는 방법 |
AU2009310352A1 (en) | 2008-10-01 | 2010-05-06 | The University Of North Carolina At Chapel Hill | Hematopoietic protection against ionizing radiation using selective cyclin-dependent kinase 4/6 inhibitors |
CN102231984A (zh) * | 2008-10-01 | 2011-11-02 | 北卡罗来纳大学查珀尔希尔分校 | 使用选择性细胞周期蛋白依赖性激酶4/6抑制剂对抗化疗化合物的造血防护 |
KR101639098B1 (ko) | 2009-03-26 | 2016-07-12 | 풀매트릭스 오퍼레이팅 컴퍼니, 인크 | 폐 질환 치료용 건조 분말 제형 및 방법 |
CA2761896A1 (en) | 2009-05-13 | 2010-11-18 | The University Of North Carolina At Chapel Hill | Cyclin dependent kinase inhibitors and methods of use |
ES2824842T3 (es) | 2009-07-13 | 2021-05-13 | Patheon Api Services Inc | Síntesis de prostanoides |
EP2461805B1 (en) * | 2009-07-24 | 2017-11-01 | University of Tennessee Research Foundation | Spectinamides as anti-tuberculosis agents |
RU2012108849A (ru) * | 2009-08-10 | 2013-09-20 | П2-Сайенс Апс | Utp для диагностирования стеноза и других состояний ограниченного кровотока |
WO2011161212A1 (en) * | 2010-06-23 | 2011-12-29 | P2-Science Aps | Combined flow directed intraarterial microcatheter for the infusion of hyperemic agent and concomitant pressure measurements for diagnostic purposes |
EP2464346A1 (en) | 2010-08-30 | 2012-06-20 | Pulmatrix, Inc. | Treatment of cystic fibrosis using calcium lactate, leucine and sodium chloride in a respiraple dry powder |
AU2011296343B2 (en) | 2010-08-30 | 2015-12-10 | Pulmatrix Operating Company, Inc. | Dry powder formulations and methods for treating pulmonary diseases |
DK3470057T3 (da) | 2010-09-29 | 2021-11-22 | Pulmatrix Operating Co Inc | Kationiske tørpulvere omfattende magnesiumsalt |
JP5877204B2 (ja) | 2010-09-29 | 2016-03-02 | パルマトリックス,インコーポレイテッド | 吸入用の一価金属カチオン乾燥粉末 |
WO2012068381A2 (en) | 2010-11-17 | 2012-05-24 | The University Of North Carolina At Chapel Hill | Protection of renal tissues from schema through inhibition of the proliferative kisses cdk4 and cdk6 |
CN103732213A (zh) | 2011-06-07 | 2014-04-16 | 帕里昂科学公司 | 治疗方法 |
US8945605B2 (en) * | 2011-06-07 | 2015-02-03 | Parion Sciences, Inc. | Aerosol delivery systems, compositions and methods |
AR086745A1 (es) | 2011-06-27 | 2014-01-22 | Parion Sciences Inc | 3,5-diamino-6-cloro-n-(n-(4-(4-(2-(hexil(2,3,4,5,6-pentahidroxihexil)amino)etoxi)fenil)butil)carbamimidoil)pirazina-2-carboxamida |
WO2013130767A1 (en) | 2012-02-29 | 2013-09-06 | Pulmatrix, Inc. | Inhalable dry powders |
US9833207B2 (en) | 2012-08-08 | 2017-12-05 | William Harrison Zurn | Analysis and clearing module, system and method |
EP2931712B8 (en) | 2012-12-17 | 2018-05-23 | Parion Sciences, Inc. | 3,5-diamino-6-chloro-n-(n-(4-phenylbutyl)carbamimidoyl) pyrazine-2- carboxamide compounds |
UA120343C2 (uk) | 2012-12-17 | 2019-11-25 | Періон Сайєнсіз, Інк. | Похідні хлорпіразинкарбоксаміду, які мають активність блокування епітеліальних натрієвих каналів |
US9962533B2 (en) | 2013-02-14 | 2018-05-08 | William Harrison Zurn | Module for treatment of medical conditions; system for making module and methods of making module |
JP6435315B2 (ja) | 2013-03-15 | 2018-12-05 | ジー1、セラピューティクス、インコーポレイテッドG1 Therapeutics, Inc. | 高活性抗新生物薬及び抗増殖剤 |
HUE046653T2 (hu) | 2013-03-15 | 2020-03-30 | G1 Therapeutics Inc | Normál sejtek tranziens védelme kemoterápia során |
RU2015146871A (ru) | 2013-04-01 | 2017-05-10 | Пулматрикс, Инк. | Сухие порошки с тиотропием |
WO2015048736A1 (en) | 2013-09-30 | 2015-04-02 | Irix Pharmaceuticals, Inc. | Novel synthesis routes for prostaglandins and prostaglandin intermediates using metathesis |
US9102633B2 (en) | 2013-12-13 | 2015-08-11 | Parion Sciences, Inc. | Arylalkyl- and aryloxyalkyl-substituted epithelial sodium channel blocking compounds |
US20150297606A1 (en) | 2014-04-17 | 2015-10-22 | G1 Therapeutics, Inc. | Tricyclic Lactams for Use in the Protection of Hematopoietic Stem and Progenitor Cells Against Ionizing Radiation |
EP3191098A4 (en) | 2014-09-12 | 2018-04-25 | G1 Therapeutics, Inc. | Combinations and dosing regimes to treat rb-positive tumors |
WO2016040848A1 (en) | 2014-09-12 | 2016-03-17 | G1 Therapeutics, Inc. | Treatment of rb-negative tumors using topoisomerase inhibitors in combination with cyclin dependent kinase 4/6 inhibitors |
CN104306028B (zh) * | 2014-09-26 | 2016-08-17 | 张清玲 | 一种用于呼吸道细菌16S rRNA基因序列检测的痰液收集方法 |
WO2017035401A1 (en) | 2015-08-26 | 2017-03-02 | Achillion Pharmaceuticals, Inc. | Amide compounds for treatment of immune and inflammatory disorders |
WO2017035405A1 (en) | 2015-08-26 | 2017-03-02 | Achillion Pharmaceuticals, Inc. | Amino compounds for treatment of immune and inflammatory disorders |
US11702672B2 (en) | 2016-02-08 | 2023-07-18 | University Of Iowa Research Foundation | Methods to produce chimeric adeno-associated virus/bocavirus parvovirus |
AU2017229347A1 (en) | 2016-03-07 | 2018-11-01 | University Of Iowa Research Foundation | AAV-mediated expression using a synthetic promoter and enhancer |
CN109789143A (zh) | 2016-07-01 | 2019-05-21 | G1治疗公司 | 基于嘧啶的抗增殖剂 |
US10413583B2 (en) | 2016-11-30 | 2019-09-17 | The University Of Chicago | Synthetic substrates for enzymes that catalyze reactions of modified cysteines and related methods |
WO2018132747A1 (en) | 2017-01-13 | 2018-07-19 | University Of Iowa Research Foundation | Bocaparvovirus small noncoding rna and uses thereof |
IL294069B2 (en) | 2017-03-01 | 2023-11-01 | Achillion Pharmaceuticals Inc | Aryl, heteroaryl and heterocyclic pharmaceutical compounds for the treatment of medical disorders |
WO2018160891A1 (en) | 2017-03-01 | 2018-09-07 | Achillion Pharmaceutical, Inc. | Pharmaceutical compounds for treatment of medical disorders |
GB2604314A (en) * | 2017-09-22 | 2022-09-07 | Nerudia Ltd | Device, system and method |
US11439608B2 (en) | 2017-09-25 | 2022-09-13 | Qun Lu | Roles of modulators of intersectin-CDC42 signaling in Alzheimer's disease |
WO2019113210A1 (en) | 2017-12-05 | 2019-06-13 | Anthos Partners, Lp | Phosphonium-based ionic drug conjugates |
US11814363B2 (en) | 2018-09-06 | 2023-11-14 | Achillion Pharmaceuticals, Inc. | Morphic forms of danicopan |
US11814391B2 (en) | 2018-09-06 | 2023-11-14 | Achillion Pharmaceuticals, Inc. | Macrocyclic compounds for the treatment of medical disorders |
BR112021005506A2 (pt) | 2018-09-25 | 2021-06-15 | Achillion Pharmaceuticals, Inc. | formas mórficas de inibidores de fator complementar d |
US10988479B1 (en) | 2020-06-15 | 2021-04-27 | G1 Therapeutics, Inc. | Morphic forms of trilaciclib and methods of manufacture thereof |
Family Cites Families (13)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB1055465A (en) * | 1962-09-27 | 1967-01-18 | Vantorex Ltd | Allergenic aerosol compositions |
BE639386A (no) * | 1962-10-30 | |||
US4132600A (en) * | 1977-06-01 | 1979-01-02 | Massachusetts Institute Of Technology | Enzymatic noninvasive method for detecting cancer |
US4501729A (en) * | 1982-12-13 | 1985-02-26 | Research Corporation | Aerosolized amiloride treatment of retained pulmonary secretions |
FR2571257A1 (fr) * | 1984-08-06 | 1986-04-11 | Gros Pierre | Composition destinee a l'humidification de la muqueuse rhino-pharyngee |
US5470838A (en) * | 1987-10-28 | 1995-11-28 | Pro-Neuron, Inc. | Method of delivering exogenous uridine or cytidine using acylated uridine or cytidine |
US4950477A (en) * | 1988-08-23 | 1990-08-21 | Memorial Hospital For Cancer And Allied Dieseas | Method of preventing and treating pulmonary infection by fungi using aerosolized polyenes |
GB9027968D0 (en) * | 1990-12-22 | 1991-02-13 | Fisons Plc | Method of treatment |
EP0517573A1 (fr) * | 1991-06-05 | 1992-12-09 | Synthelabo | Compositions pharmaceutiques pour le traitement des affections des voies respiratoires |
US5292498A (en) * | 1991-06-19 | 1994-03-08 | The University Of North Carolina At Chapel Hill | Method of treating lung disease with uridine triphosphates |
US5567689A (en) * | 1993-08-13 | 1996-10-22 | The Uab Research Foundation | Methods for increasing uridine levels with L-nucleosides |
US5656256A (en) * | 1994-12-14 | 1997-08-12 | The University Of North Carolina At Chapel Hill | Methods of treating lung disease by an aerosol containing benzamil or phenamil |
US5628984A (en) * | 1995-07-31 | 1997-05-13 | University Of North Carolina At Chapel Hill | Method of detecting lung disease |
-
1995
- 1995-07-31 US US08/509,052 patent/US5628984A/en not_active Expired - Lifetime
-
1996
- 1996-07-24 IL IL12280396A patent/IL122803A0/xx unknown
- 1996-07-24 WO PCT/US1996/012377 patent/WO1997005195A1/en active IP Right Grant
- 1996-07-24 DE DE69633449T patent/DE69633449T2/de not_active Expired - Fee Related
- 1996-07-24 US US08/776,772 patent/US6133247A/en not_active Expired - Lifetime
- 1996-07-24 NZ NZ313864A patent/NZ313864A/xx unknown
- 1996-07-24 JP JP50781797A patent/JP3623237B2/ja not_active Expired - Fee Related
- 1996-07-24 CN CN96195803A patent/CN1121441C/zh not_active Expired - Fee Related
- 1996-07-24 AU AU66399/96A patent/AU705528B2/en not_active Ceased
- 1996-07-24 CA CA002226892A patent/CA2226892A1/en not_active Abandoned
- 1996-07-24 KR KR1019980700675A patent/KR100283306B1/ko not_active IP Right Cessation
- 1996-07-24 EP EP96926158A patent/EP0841900B1/en not_active Expired - Lifetime
- 1996-07-24 AT AT96926158T patent/ATE276740T1/de not_active IP Right Cessation
- 1996-07-24 BR BR9610059A patent/BR9610059A/pt not_active Application Discontinuation
- 1996-07-24 MX MX9800933A patent/MX9800933A/es not_active IP Right Cessation
- 1996-07-24 ES ES96926158T patent/ES2229281T3/es not_active Expired - Lifetime
- 1996-07-29 ZA ZA9606425A patent/ZA966425B/xx unknown
- 1996-12-30 US US08/777,026 patent/US5902567A/en not_active Expired - Lifetime
-
1998
- 1998-01-21 NO NO980279A patent/NO980279D0/no not_active Application Discontinuation
-
1999
- 1999-11-04 US US09/433,757 patent/US6214536B1/en not_active Expired - Lifetime
-
2002
- 2002-08-05 JP JP2002227140A patent/JP2003073280A/ja active Pending
Also Published As
Publication number | Publication date |
---|---|
MX9800933A (es) | 1998-05-31 |
JP3623237B2 (ja) | 2005-02-23 |
ATE276740T1 (de) | 2004-10-15 |
US5902567A (en) | 1999-05-11 |
KR100283306B1 (ko) | 2001-03-02 |
EP0841900A4 (no) | 1998-06-10 |
IL122803A0 (en) | 1998-09-16 |
WO1997005195A1 (en) | 1997-02-13 |
CN1191553A (zh) | 1998-08-26 |
US6214536B1 (en) | 2001-04-10 |
AU6639996A (en) | 1997-02-26 |
EP0841900A1 (en) | 1998-05-20 |
ZA966425B (en) | 1997-02-19 |
DE69633449T2 (de) | 2006-04-27 |
ES2229281T3 (es) | 2005-04-16 |
JPH11509759A (ja) | 1999-08-31 |
US6133247A (en) | 2000-10-17 |
KR19990036011A (ko) | 1999-05-25 |
NZ313864A (en) | 2000-04-28 |
EP0841900B1 (en) | 2004-09-22 |
CN1121441C (zh) | 2003-09-17 |
CA2226892A1 (en) | 1997-02-13 |
US5628984A (en) | 1997-05-13 |
NO980279D0 (no) | 1998-01-21 |
BR9610059A (pt) | 1999-03-02 |
JP2003073280A (ja) | 2003-03-12 |
AU705528B2 (en) | 1999-05-27 |
DE69633449D1 (de) | 2004-10-28 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
NO980279L (no) | Fremgangsmåte til detektering av lungesykdom | |
US5763447C1 (en) | Method of preventing or treating pneumonia in immobilized patients with uridine triphosphates and related compounds | |
HUP0203728A2 (hu) | Formoterolt tartalmazó aeroszolkészítmény | |
HK1076379A1 (en) | Use of a composition comprising anti-vla-1 antibody for the preparation of a pharmaceutical composition for the treatment of pulmonary fibrosis | |
MXPA01008547A (es) | Metodo para promover la hidratacion de mucosas con ciertos difosfatos de uridina, adenina y citidina, y analogos de estos. | |
JPH09501413A (ja) | 滞留肺分泌物の治療方法 | |
MY120023A (en) | Method of treating dry eye disease with uridine triphosphates and related compounds. | |
CA2250188A1 (en) | Method of treating ciliary dyskinesia with uridine triphosphates and related compounds | |
BR9915592A (pt) | Processos para conversão das regiões cristalinas meta-estáveis e/ou amorfas de partìculas pré-formadas para um estado essencialmente cristalino para tratamento de uma condição alérgica e/ou inflamatória do nariz ou dos pulmões, para tratamento de doença pulmonar obstrutiva crÈnica (copd), rinite ou asma e para tratamento de doenças de intestino inflamatório (ibd), doença de crohn ou colite ulcerativa, formulação farmacêutica, uso da mesma, partìculas no estado essencialmente cristalino, e, partìculas de lactose mono-hidratada no estado essencialmente cristalino | |
ATE225663T1 (de) | Verfahren zur behandlung von mittelohrentzündung mittels uridintriphosphaten und verwandten mitteln | |
KR100518066B1 (ko) | 우리딘 트리포스페이트 및 관련 화합물로 기관지염을 치료하는방법 | |
DK0630230T3 (da) | Farmaceutiske inhaleringspræparater | |
DE69533128D1 (de) | Pharmazeutische akzeptabel dnase zusammensetzung | |
CA2240717A1 (en) | Method of treating and diagnosing sleep disordered breathing and means for carrying out the method | |
ES2122015T3 (es) | Uso de urodilatina en enfermedades pulmonares y bronquiales. | |
BR9809678A (pt) | Derivados de triptolìdeo úteis no tratamento de doenças autoimunes | |
KR890012942A (ko) | 5-치환된 오르니틴 유도체 | |
HUP0201629A2 (hu) | Eletriptánt és ciklodextrinszármazékot tartalmazó gyógyászati komplex, ezt tartalmazó gyógyszerkészítmény, eljárás az előállítására és alkalmazása | |
KR910009255A (ko) | 과트리글리세라이드혈증과, 콜레스테롤혈증, 저레벨의 hdl질환 및 아테롬성 동맥경화증 치료제로서 사용되는 2-(페녹시 프로파놀아미노)에톡시 페녹시아세트산 유도체 | |
RU95120783A (ru) | Способ профилактики и лечения атеросклероза | |
Bishara et al. | Lichenoid reaction in bone marrow transplants suffering from chronic GVHD is associated with HLA-DQW1 | |
NO930711L (no) | Aminosyrederivater ringsluttet i den c-terminale ende | |
FI991115A0 (fi) | Menetelmä oraalisesti elimistöön tuotavan ravinteen tai muun fysiologisesti vaikuttavan aineen maittavuuden biokyberneettiseksi manipuloimiseksi sekä menetelmän käyttämiseen liittyvä valmiste |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FC2A | Withdrawal, rejection or dismissal of laid open patent application |